latest update:
[TrialBase DB]

trial summary · NCT07825064

Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma

A Phase II, Single Arm, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination With Pomalidomide and Dexamethasone in Patients With Multiple Myeloma Who Have Received a Prior BCMA-Targeting CAR T-Cell Therapy

Trial record from the TrialBase DB dataset, status RECRUITING, condition Multiple Myeloma, sponsored by Hoffmann-La Roche. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07825064phase PHASE2enrollment 45start 2026-10-30

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) in patients with multiple myeloma (MM) who have received one to four prior lines of therapy and have been exposed to an anti-cluster of differentiation 38 (CD38) antibody, lenalidomide, a proteasome inhibitor (PI) and a B cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T-cell therapy.

Source record: https://clinicaltrials.gov/study/NCT07825064

Facts

registry idNCT07825064
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE2
study typeINTERVENTIONAL
lead conditionMultiple Myeloma
sponsorHoffmann-La Roche
sponsor classINDUSTRY
enrollment45
start date2026-10-30
primary completion2029-04-13
completion2031-01-19
results postednot reported

Conditions

  • Multiple Myeloma

Interventions

  • Cevostamab
  • Pomalidomide
  • Dexamethasone
  • Tocilizumab

Countries

  • Germany

Intervention types: DRUG

Work with this record